<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">26312694</article-id>
      <article-id pub-id-type="pmc">4540528</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20153893</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Anti-TNF-&#x3B1; and hydralazine drug-induced lupus<xref ref-type="fn" rid="fn01">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Quaresma</surname>
            <given-names>Maria Vict&#xF3;ria</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
          <xref ref-type="corresp" rid="c01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bernardes Filho</surname>
            <given-names>Fred</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Fernanda Brand&#xE3;o</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pockstaller</surname>
            <given-names>Mercedes Prates</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dias</surname>
            <given-names>Maria Fernanda Reis Gavazzoni</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Azulay</surname>
            <given-names>David Rubem</given-names>
          </name>
          <xref ref-type="aff" rid="aff01">1</xref>
        </contrib>
        <aff id="aff01"><label>1</label>Instituto de Dermatologia Professor Rubem David Azulay -
Santa Casa da Miseric&#xF3;rdia do Rio de Janeiro - Rio de Janeiro (RJ), Brazil.</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c01">MAILING ADDRESS: Alameda Itu, 1030, 9B. Jardim Paulista, 01421-001 -
S&#xE3;o Paulo - SP, Brazil. E-mail: <email>mavi@mavictoria.com.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>May-Jun</season>
        <year>2015</year>
      </pub-date>
      <volume>90</volume>
      <issue>3 Suppl 1</issue>
      <fpage>125</fpage>
      <lpage>129</lpage>
      <history>
        <date date-type="received">
          <day>31</day>
          <month>7</month>
          <year>2014</year>
        </date>
        <date date-type="accepted">
          <day>05</day>
          <month>9</month>
          <year>2014</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; 2015 by Anais Brasileiros de Dermatologia</copyright-statement>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Drug-induced lupus is a rare drug reaction featuring the same symptoms as idiopathic
lupus erythematosus. Recently, with the introduction of new medicines in clinical
practice, an increase in the number of illness-triggering implicated drugs has been
reported, with special emphasis on anti-TNF-&#x3B1; drugs. In the up-to-date list,
almost one hundred medications have been associated with the occurrence of
drug-induced lupus. The authors present two case reports of the illness induced
respectively by hydralazine and infliximab, addressing the clinical and laboratorial
characteristics, diagnosis, and treatment.</p>
      </abstract>
      <kwd-group>
        <kwd>Acetyl-CoA C-Acetyltransferase</kwd>
        <kwd>Acetylation</kwd>
        <kwd>Autoimmunity</kwd>
        <kwd>Hydralazine</kwd>
        <kwd>Lupus erythematosus, cutaneous</kwd>
        <kwd>Tumor necrosis factor-alpha</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>INTRODUCTION</title>
      <p>Drug-induced lupus (DIL) was first reported in 1945 by Hoffman and it is estimated that
over 10% of the cases of systemic lupus erythematosus (SLE) are drug-induced. <sup><xref rid="r01" ref-type="bibr">1</xref>,<xref rid="r02" ref-type="bibr">2</xref></sup>
Although the pathogenesis is not completely understood, genetic predisposition plays an
important role.<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup> There is evidence of greater association in slow,
acetylating patients, in which there is a genetically-mediated reduction of the
synthesis of N-acetyltransferase. The anti-histone antibodies are considered markers of
DIL.<sup><xref rid="r05" ref-type="bibr">5</xref></sup></p>
      <p>The clinical presentation is of insidious onset and can be similar to that of SLE,
chronic or subacute cutaneous lupus erythematosus.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r06" ref-type="bibr">6</xref></sup> The most common symptoms
are arthralgia and arthritis, sudden erythema and polycyclic lesions located in
sun-exposed areas, similar to the presentation of subacute lupus erythematosus. Severe
systemic involvement is rare, with fewer occurrences of alterations in the central
nervous, renal, and hematopoietic systems.<sup><xref rid="r04" ref-type="bibr">4</xref>,<xref rid="r07" ref-type="bibr">7</xref></sup></p>
      <p>Recently, with the introduction of new drugs in clinical practice, an increase in the
number of drugs causing the disease has been reported.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Anti-TNF therapies (infliximab, etanercept and
adalimumab) are considered potential inducers of SLE.<sup><xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> The clinical and
laboratory tests differ from classically described DIL.</p>
      <p>In the case of DIL associated with anti-TNF-&#x3B1;, the positivity of doubled strand-
DNA antibodies (DS-DNA) is most commonly observed.<sup><xref rid="r09" ref-type="bibr">9</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup> Although the
pathogenesis of SLE induced by anti-TNF is not fully elucidated, drug interruption is
the mainstay of the treatment, which is also the first step when DIL is secondary to
other drugs. <sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup> In addition, the use of medications to control symptoms,
such as anti-inflammatory drugs (NSAIDs), can be indicated. In extensive or refractory
cases, systemic corticosteroid may be employed until clinical symptons
resolve.<sup><xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup></p>
      <p>This paper presents two cases of hydralazine- and infliximab-induced lupus with clinical
and histopathologic features. The authors suggest that the two conditions are different
based on distinct pathogenesis.</p>
    </sec>
    <sec>
      <title>CASE REPORT</title>
      <p>Case 1: A 54-year-old male patient with hypertension, taking hydralazine for four years,
had been presenting with been presenting erythematous, scaly and edematous papules on
the trunk, back, upper limbs and sun-exposed areas for the last two months (<xref ref-type="fig" rid="f01">Figure 1</xref>). Laboratory tests: ANA 1:640 homogeneous
nuclear pattern and positive anti-histone. Histopathology was compatible with lupus
erythematosus (<xref ref-type="fig" rid="f02">Figure 2</xref>). Hydralazine was
discontinued and prednisone was prescribed. There was rapid improvement of skin lesions,
and resolution of symptoms after 4 weeks (<xref ref-type="fig" rid="f03">Figure
3</xref>).</p>
      <fig id="f01" orientation="portrait" position="float">
        <label>FIGURE 1</label>
        <caption>
          <p>Drug-induced lupus by hydralazine. Erythematous, scaly and edematous papules on
the back <bold>(A)</bold>, trunk and upper limbs <bold>(B)</bold></p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0125-g01"/>
      </fig>
      <fig id="f02" orientation="portrait" position="float">
        <label>FIGURE 2</label>
        <caption>
          <p>Drug-induced lupus by hydralazine. Histopathology: hyperkeratosis, thinning of the
epidermis, vacuolar degeneration of the basal layer (A - white arrow),
keratinocyte apoptosis, pigmentary incontinence, perivascular and periadnexal infi
ltrate. Thickening and hyalinization of the basement membrane (B - white
arrow)</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0125-g02"/>
      </fig>
      <fig id="f03" orientation="portrait" position="float">
        <label>FIGURE 3</label>
        <caption>
          <p>Drug-induced lupus by hydralazine. Fig. <bold>(A,</bold>
<bold>B)</bold>: There was rapid improvement of skin lesions. Fig. <bold>(C,
D)</bold>: Resolution of symptoms after 4 weeks of drug discontinuation</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0125-g03"/>
      </fig>
      <p>Case 2: A 37-year-old male patient, bearer of ulcerative colitis, started on infliximab
at a dose of 5 mg/kg. After a two-month therapy he presented erythematous, brownish,
infiltrated, rough surface lesions on the face and ear lobes (<xref ref-type="fig" rid="f04">Figure 4</xref>). Laboratory test: ANA 1:320 with peripheral pattern.
Histopathology was compatible with lupus erythematosus (<xref ref-type="fig" rid="f05">Figure 5</xref>).</p>
      <fig id="f04" orientation="portrait" position="float">
        <label>FIGURE 4</label>
        <caption>
          <p>Drug-induced lupus by anti-TNF-&#x3B1;. <xref ref-type="fig" rid="f04">Fig. 4
(A)</xref>: Erythematous, brownish, infiltrated, rough surface lesions on the
face. <xref ref-type="fig" rid="f04">Figure 4 (B)</xref>: The same pattern
involving preauricular and ear lobes</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0125-g04"/>
      </fig>
      <fig id="f05" orientation="portrait" position="float">
        <label>FIGURE 5</label>
        <caption>
          <p>Drug-induced lupus by anti-TNF-&#x3B1;. Fig. <bold>(A, B, C)</bold>.
Histopathology: follicular hyperkeratosis, vacuolization of the basal layer of the
epidermal and follicular epithelium, superficial perivascular mononuclear infi
ltrate and melanophages in the papillary dermis</p>
        </caption>
        <graphic xlink:href="abd-90-03-s1-0125-g05"/>
      </fig>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Drugs associated with induction of lupus erythematosus are classified into groups
according to the level of available scientific evidence of causal relationship, and
hydralazine is definitely regarded as a drug capable of inducing lupus (controlled
studies).<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Anti-TNF-&#x3B1;
therapies are drugs that have recently been reported in the induction of the
disease.<sup><xref rid="r08" ref-type="bibr">8</xref>,<xref rid="r09" ref-type="bibr">9</xref></sup> The mechanisms that induce lupus with the use of
hydralazine and anti-TNF-&#x3B1; therapies are distinct.<sup><xref rid="r02" ref-type="bibr">2</xref>,<xref rid="r07" ref-type="bibr">7</xref>,<xref rid="r08" ref-type="bibr">8</xref></sup></p>
      <p>Hydralazine is metabolizated by the liver through acetylation by the enzyme
N-acetyltransferase. The rate of acetylation is genetically determined, and the slow or
fast acetylator phenotype is controlled by a single, recessive gene associated with low
activity of hepatic acetyltransferase.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Since the elimination of hydralazine depends mainly on acetylation,
acetylate individuals may exhibit toxic and/or immunological effects, such as DIL
related to drug accumulation.<sup><xref rid="r07" ref-type="bibr">7</xref></sup>
Hydralazine also inhibits T-cell DNA methylation, which has the function of deleting
non-essential or potentially-deleterious-to-cell-function genes, and induces
self-reactivity in these cells, resulting in autoimmunity.<sup><xref rid="r04" ref-type="bibr">4</xref></sup></p>
      <p>Infliximab is a chimeric, human-murine, monoclonal antibody that binds with high
affinity to both soluble and transmembrane forms of TNF-&#x3B1;.<sup><xref rid="r08" ref-type="bibr">8</xref></sup> The development of lupus erythematosus
during anti-TNF-&#x3B1; therapy is unclear, though three mechanisms have been
proposed.<sup><xref rid="r09" ref-type="bibr">9</xref></sup> The first is that
anti-TNF-&#x3B1; inhibits Th1 cytokine production, increasing the production of Th2
cytokines, leading to the production of autoantibodies and a lupus-like
syndrome.<sup><xref rid="r10" ref-type="bibr">10</xref></sup> Another hypothesis
assumes that systemic inhibition of TNF-&#x3B1; might interfere with apoptosis,
affecting the clearance of nuclear debris and apoptotic neutrophils by phagocytes, thus
promoting the production of autoantibodies to DNA and other nuclear antigens. In the
third hypothesis, the anti-TNF-&#x3B1; therapy could inhibit cytotoxic T cells,
reducing the elimination of autoantibodies produced by B-cells.<sup><xref rid="r08" ref-type="bibr">8</xref>-<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Due to the difficulties encountered in diagnosis, some criteria were proposed<sup><xref rid="r07" ref-type="bibr">7</xref></sup> for guidance and the patient in case 1
presented enough features to be diagnosed with DIL: continuous use of the drug for at
least 60 days; sudden and persistent erythema; positive anti-histone antibodies and ANA
with titers above 1/160 and disappearance of the lesions and symptoms after at least two
weeks of drug discontinuation. In addition, the patient's histopathology was compatible
with lupus erythematosus.</p>
      <p>Certain characteristics aid in the diagnosis of anti-TNF-&#x3B1;-induced lupus: onset
of symptoms time-related to the use of anti-TNF-&#x3B1; therapy, at least one positive
serology (ANA, anti-DS-DNA) and one non-serological criterion (arthritis, serositis,
haematological disorders - anemia, leukopenia and thrombocytopenia - or malar
rash).<sup><xref rid="r03" ref-type="bibr">3</xref>,<xref rid="r04" ref-type="bibr">4</xref></sup> In case 2, the patient had the 3 main characteristics
listed above (onset of symptoms, positive serology and malar rash), in addition to
typical histopathological features of lupus erythematosus.</p>
      <p>Histopathological findings of lupus erythematosus aid in the diagnosis but are not
mentioned among the criteria for defining classic DIL or anti-TNF-&#x3B1; drug-induced
lupus.</p>
      <p>The suspension of anti-TNF-&#x3B1; therapy is controversial in asymptomatic patients
with positive ANA.<sup><xref rid="r02" ref-type="bibr">2</xref></sup> Systemic
corticosteroids were not initiated in case 2 due to the benignity of the clinical
presentation. Both patients showed clinical improvement during follow-up.</p>
      <p>The recognition of the fact that the condition is drug-induced avoids unnecessary
investigations and enables appropriate management of the patient. More studies are
necessary to better elucidate the pathogenesis of anti-TNF-induced lupus.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="conflict">
        <p>Conflict of Interest: None.</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None.</p>
      </fn>
      <fn fn-type="other">
        <p><bold>How to cite this article:</bold> Quaresma MV, Bernardes Filho F, Oliveira FB,
Pockstaller MP, Dias MFRG, Azulay DR. Anti-TNF-&#x3B1; and classical drug-induced
lupus. An Bras Dermatol. 2015;90 (3 Suppl 1):S125-9</p>
      </fn>
      <fn fn-type="other" id="fn01">
        <label>*</label>
        <p>Work performed at the Instituto de Dermatologia Professor Rubem David Azulay, Santa
Casa da Miseric&#xF3;rdia do Rio de Janeiro - Rio de Janeiro (RJ), Brasil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="r01">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hoffman</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Sensitivity to sufadizine resembling acute disseminated lupus
erythematosus</article-title>
          <source>Arch Dermatol Physiol</source>
          <year>1945</year>
          <volume>51</volume>
          <fpage>90</fpage>
          <lpage>92</lpage>
        </element-citation>
      </ref>
      <ref id="r02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mota</surname>
              <given-names>LMH</given-names>
            </name>
            <name>
              <surname>Haddad</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>RAC</given-names>
            </name>
            <name>
              <surname>Carvalho</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Muniz-Junqueira</surname>
              <given-names>MI</given-names>
            </name>
            <name>
              <surname>Neto</surname>
              <given-names>LLS</given-names>
            </name>
            <name>
              <surname>Lima</surname>
              <given-names>FAC</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced lupus - from basic to spplied immunology</article-title>
          <source>Rev Bras Reumatol</source>
          <year>2007</year>
          <volume>47</volume>
          <fpage>431</fpage>
          <lpage>437</lpage>
        </element-citation>
      </ref>
      <ref id="r03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Borba</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Latorre</surname>
              <given-names>LC</given-names>
            </name>
            <name>
              <surname>Brenol</surname>
              <given-names>JCT</given-names>
            </name>
            <name>
              <surname>Kayser</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>NA</given-names>
            </name>
            <name>
              <surname>Zimmermann</surname>
              <given-names>AF</given-names>
            </name>
          </person-group>
          <article-title>Consensus of Systemic Lupus Erythematosus</article-title>
          <source>Rev Bras Reumatol</source>
          <year>2008</year>
          <volume>48</volume>
          <fpage>196</fpage>
          <lpage>207</lpage>
        </element-citation>
      </ref>
      <ref id="r04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Petri</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Orbai</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Alarc&#xF3;n</surname>
              <given-names>GS</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Merrill</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Fortin</surname>
              <given-names>PR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Derivation and validation of the Systemic Lupus International
Collaborating Clinics classification criteria for systemic lupus
erythematosus</article-title>
          <source>Arthritis Rheum</source>
          <year>2012</year>
          <volume>64</volume>
          <fpage>2677</fpage>
          <lpage>2686</lpage>
          <pub-id pub-id-type="pmid">22553077</pub-id>
        </element-citation>
      </ref>
      <ref id="r05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Atzeni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Marrazza</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Sarzi-Puttini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Carrabba</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Drug-induced lupus erythematosus</article-title>
          <source>Reumatismo</source>
          <year>2003</year>
          <volume>55</volume>
          <fpage>147</fpage>
          <lpage>154</lpage>
          <pub-id pub-id-type="pmid">14513113</pub-id>
        </element-citation>
      </ref>
      <ref id="r06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sarzi-Puttini</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Atzeni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Capsoni</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lubrano</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Doria</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Drug induced lupus erythematosus</article-title>
          <source>Autoimmunity</source>
          <year>2005</year>
          <volume>38</volume>
          <fpage>507</fpage>
          <lpage>518</lpage>
          <pub-id pub-id-type="pmid">16373256</pub-id>
        </element-citation>
      </ref>
      <ref id="r07">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Duarte</surname>
              <given-names>AA</given-names>
            </name>
          </person-group>
          <source>Colagenoses e a Dermatologia</source>
          <edition>2. ed</edition>
          <publisher-loc>S&#xE3;o Paulo</publisher-loc>
          <publisher-name>DiLivros</publisher-name>
          <year>2012</year>
        </element-citation>
      </ref>
      <ref id="r08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almoallim</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Al-Ghamdi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Almaghrabi</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Alyasi</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
          <article-title>Anti-Tumor Necrosis Factor-a Induced Systemic Lupus
Erythematosus</article-title>
          <source>Open Rheumatol J</source>
          <year>2012</year>
          <volume>6</volume>
          <fpage>315</fpage>
          <lpage>319</lpage>
          <pub-id pub-id-type="pmid">23198006</pub-id>
        </element-citation>
      </ref>
      <ref id="r09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wetter</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Davis</surname>
              <given-names>MD</given-names>
            </name>
          </person-group>
          <article-title>Lupus-like syndrome attributable to anti-tumor necrosis factor alpha
therapy in 14 patients during an 8-year period at Mayo Clinic</article-title>
          <source>Mayo Clin Proc</source>
          <year>2009</year>
          <volume>84</volume>
          <fpage>979</fpage>
          <lpage>984</lpage>
          <pub-id pub-id-type="pmid">19880688</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Azulay</surname>
              <given-names>RD</given-names>
            </name>
            <name>
              <surname>Azulay</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <chapter-title>Doen&#xE7;as Autoimunes de Interesse Dermatol&#xF3;gico</chapter-title>
          <person-group person-group-type="author">
            <name>
              <surname>Azulay</surname>
              <given-names>DR</given-names>
            </name>
          </person-group>
          <source>Dermatologia</source>
          <edition>6 ed</edition>
          <publisher-loc>Rio de Janeiro</publisher-loc>
          <publisher-name>Guanabara Koogan</publisher-name>
          <year>2013</year>
          <fpage>778</fpage>
          <lpage>781</lpage>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
